Use of CGM in type 1 diabetes patients may lower odds of developing retinopathy: Study
Diabetic retinopathy (DR) is a serious complication of type 1 diabetes (T1D) that can lead to vision impairment or blindness if left untreated. Understanding the impact of diabetes management technologies, such as continuous glucose monitoring (CGM) and insulin pumps, on DR outcomes is crucial for improving patient care and outcomes. The use of CGM and insulin pumps has revolutionized diabetes management by providing real-time glucose data and precise insulin delivery.
A recent retrospective cohort study aimed to evaluate the association between CGM, insulin pump use, or both, and the development of DR and proliferative diabetic retinopathy (PDR) in adults with T1D. This study was published in JAMA Network Open by T. Y. Alvin and colleagues.
The study included 550 adults with T1D from a tertiary diabetes center and ophthalmology center. Data were analyzed retrospectively from 2013 to 2021. Participants were categorized based on their use of diabetes technologies, including CGM, insulin pump, or both.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.